{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:18:09Z","timestamp":1793369889268,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.lfs.2025.124176","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:58:28Z","timestamp":1766591908000},"page":"124176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["PACAP: A promising disease-modifying target for Alzheimer's disease"],"prefix":"10.1016","volume":"386","author":[{"given":"Rehana","family":"Basri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2025.124176_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1017\/S1041610203008664","article-title":"The ABC of Alzheimer\u2019s disease: cognitive changes and their management in Alzheimer\u2019s disease and related dementias","volume":"14","author":"Corey-Bloom","year":"2002","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.lfs.2025.124176_bb0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-94-007-5416-4_14","article-title":"Alzheimer\u2019s disease","volume":"65","author":"De-Paula","year":"2012","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.lfs.2025.124176_bb0015","article-title":"Mitigating seizure-induced cognitive deficits in mice induced with pentylenetetrazol by roflumilast through targeting the NLRP3 inflammasome\/BDNF\/SIRT3 pathway and regulating ferroptosis","volume":"366\u2013367","author":"Fawzy","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2025.124176_bb0020","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2005.01.040","article-title":"Intraneuronal A\u03b2 causes the onset of early Alzheimer\u2019s disease-related cognitive deficits in transgenic mice","volume":"45","author":"Billings","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.lfs.2025.124176_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.14283\/jpad.2021.15","article-title":"The epidemiology of Alzheimer\u2019s disease modifiable risk factors and prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.lfs.2025.124176_bb0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00109-016-1427-y","article-title":"Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders","volume":"94","author":"Mahley","year":"2016","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.lfs.2025.124176_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer\u2019s disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.124176_bb0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","article-title":"15-Year longitudinal study of blood pressure and dementia","volume":"347","author":"Skoog","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2025.124176_bb0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrneurol.2011.60","article-title":"Depression and risk of developing dementia","volume":"7","author":"Byers","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.lfs.2025.124176_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.smrv.2017.06.010","article-title":"Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis","volume":"40","author":"Shi","year":"2018","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.lfs.2025.124176_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1750-3639.2011.00539.x","article-title":"Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer\u2019s disease?","volume":"22","author":"Strang","year":"2012","journal-title":"Brain Pathol."},{"key":"10.1016\/j.lfs.2025.124176_bb0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuint.2011.12.007","article-title":"Promotion of \u03b2-amyloid production by C-reactive protein and its implications in the early pathogenesis of Alzheimer\u2019s disease","volume":"60","author":"Bi","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.lfs.2025.124176_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/srep13281","article-title":"Monomeric C-reactive protein - a key molecule driving development of Alzheimer\u2019s disease associated with brain ischaemia?","volume":"5","author":"Slevin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.124176_bb0070","doi-asserted-by":"crossref","DOI":"10.1159\/000442585","article-title":"Elevated C-reactive protein is associated with cognitive decline in outpatients of a general hospital: the project in Sado for total health (PROST)","author":"Watanabe","year":"2016","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"10.1016\/j.lfs.2025.124176_bb0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0140-6736(93)91705-Q","article-title":"Apolipoprotein E polymorphism and Alzheimer\u2019s disease","volume":"342","author":"Poirier","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2025.124176_bb0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2016.03.005","article-title":"Acetylated Tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes Tauopathy-related memory loss","volume":"90","author":"Tracy","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.lfs.2025.124176_bb0085","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer\u2019s disease","volume":"18","author":"Khan","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.lfs.2025.124176_bb0090","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2025.124176_bb0095","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-170672","article-title":"Memantine for the treatment of dementia: a review on its current and future applications","volume":"62","author":"Folch","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2025.124176_bb0100","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/CON.0000000000001503","article-title":"Treatment of Alzheimer disease","volume":"30","author":"Geldmacher","year":"2024","journal-title":"CONTINUUM Lifelong Learn. Neurol."},{"key":"10.1016\/j.lfs.2025.124176_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer\u2019s disease: treatment strategies and their limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.124176_bb0110","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.3390\/ijms25115803","article-title":"Roles of cytokines in Alzheimer\u2019s disease","volume":"25","author":"Chen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.124176_bb0115","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1096\/fj.10-180133","article-title":"Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer\u2019s disease-like pathology in amyloid precursor protein-transgenic mice","volume":"25","author":"Rat","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2025.124176_bb0120","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.neurobiolaging.2014.03.022","article-title":"Pituitary adenylate cyclase-activating polypeptide protects against \u03b2-amyloid toxicity","volume":"35","author":"Han","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.lfs.2025.124176_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1515\/cmble-2015-0008","article-title":"Therapeutic potential of PACAP for neurodegenerative diseases","volume":"20","author":"Yang","year":"2015","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.lfs.2025.124176_bb0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","article-title":"Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells","volume":"164","author":"Miyata","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2025.124176_bb0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/pr.109.001370","article-title":"Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery","volume":"61","author":"Vaudry","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2025.124176_bb0140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1432-1033.1992.tb17043.x","article-title":"Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes: discovery of PACAP(6\u201338) as a potent antagonist","volume":"207","author":"Robberecht","year":"1992","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.lfs.2025.124176_bb0145","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.peptides.2007.04.026","article-title":"Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology","volume":"28","author":"Laburthe","year":"2007","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.124176_bb0150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/biomedicines10020406","article-title":"Signal transduction by VIP and PACAP receptors","volume":"10","author":"Langer","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.lfs.2025.124176_bb0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pharmthera.2008.11.006","article-title":"VPAC and PAC receptors: from ligands to function","volume":"121","author":"Dickson","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2025.124176_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fendo.2013.00055","article-title":"Alternative splicing of the pituitary adenylate cyclase-activating polypeptide receptor PAC1: mechanisms of fine tuning of brain activity","volume":"4","author":"Blechman","year":"2013","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.lfs.2025.124176_bb0165","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2174\/1381612043383548","article-title":"Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide","volume":"10","author":"Somogyvari-Vigh","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2025.124176_bb0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neuro.2018.03.010","article-title":"Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents","volume":"66","author":"Reglodi","year":"2018","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.lfs.2025.124176_bb0175","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2174\/138161211795589355","article-title":"Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo","volume":"17","author":"Reglodi","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2025.124176_bb0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fendo.2020.00377","article-title":"Protective effects of PACAP in peripheral organs","volume":"11","author":"Toth","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.lfs.2025.124176_bb0185","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5483\/BMBRep.2014.47.7.086","article-title":"Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases","volume":"47","author":"Lee","year":"2014","journal-title":"BMB Rep."},{"key":"10.1016\/j.lfs.2025.124176_bb0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12031-008-9070-x","article-title":"PACAP has anti-apoptotic effect in the salivary gland of an invertebrate species, Helix pomatia","volume":"36","author":"Pirger","year":"2008","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2025.124176_bb0195","first-page":"3730","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP) as a potential therapeutic agent in Parkinson\u2019s disease","volume":"22","author":"Reglodi","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2025.124176_bb0200","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.2174\/092986709789712899","article-title":"Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective peptide","volume":"16","author":"Bourgault","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lfs.2025.124176_bb0205","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/bph.12181","article-title":"VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair","volume":"169","author":"Waschek","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2025.124176_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0845-3","article-title":"Protective effects of PACAP in ischemia","volume":"19","author":"Reglodi","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.lfs.2025.124176_bb0215","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1212\/WNL.0000000000000417","article-title":"Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease","volume":"82","author":"Han","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2025.124176_bb0220","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1073\/pnas.0205689101","article-title":"Amyloid \u03b2 peptide load is correlated with increased \u03b2-secretase activity in sporadic Alzheimer\u2019s disease patients","volume":"101","author":"Li","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2025.124176_bb0225","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","article-title":"Soluble amyloid \u03b2 peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease","volume":"155","author":"Lue","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2025.124176_bb0230","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1101\/lm.34200","article-title":"PACAP-38 enhances excitatory synaptic transmission in the rat hippocampal CA1 region","volume":"7","author":"Roberto","year":"2000","journal-title":"Learn. Mem."},{"key":"10.1016\/j.lfs.2025.124176_bb0235","doi-asserted-by":"crossref","first-page":"11374","DOI":"10.1523\/JNEUROSCI.3871-05.2005","article-title":"Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G\u03b1q, protein kinase C, and activation of Src","volume":"25","author":"Macdonald","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2025.124176_bb0240","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.neuroscience.2005.11.028","article-title":"Pituitary adenylate cyclase activating polypeptide reduces expression of Kv1.4 and Kv4.2 subunits underlying A-type K+ current in adult mouse olfactory neuroepithelia","volume":"138","author":"Han","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2025.124176_bb0245","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.neuroscience.2005.05.007","article-title":"Pituitary adenylate cyclase activating polypeptide reduces A-type K + currents and caspase activity in cultured adult mouse olfactory neurons","volume":"134","author":"Han","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2025.124176_bb0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.peptides.2012.05.021","article-title":"Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins","volume":"36","author":"Nonaka","year":"2012","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.124176_bb0255","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12031-025-02366-z","article-title":"More than three decades after discovery of the neuroprotective effect of PACAP, what is still preventing its clinical use?","volume":"75","author":"Cherait","year":"2025","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2025.124176_bb0260","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.peptides.2012.05.021","article-title":"Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins","volume":"36","author":"Nonaka","year":"2012","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.124176_bb0265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jamaneurol.2014.3625","article-title":"Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease","volume":"72","author":"Han","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.lfs.2025.124176_bb0270","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1096\/fj.10-180133","article-title":"Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer\u2019s disease-like pathology in amyloid precursor protein-transgenic mice","volume":"25","author":"Rat","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2025.124176_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082032","article-title":"The potential of the nose-to-brain delivery of PACAP for the treatment of neuronal disease","volume":"15","author":"Cherait","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2025.124176_bb0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/156720512799361655","article-title":"Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking","volume":"9","author":"Lichtenthaler","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.lfs.2025.124176_bb0285","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-023-01072-w","article-title":"Therapeutic potential of ADAM10 modulation in Alzheimer\u2019s disease: a review of the current evidence","volume":"21","author":"Khezri","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.lfs.2025.124176_bb0290","series-title":"PACAP modulates distinct neuronal components to induce cell-specific plasticity at central and autonomic synapses","first-page":"83","author":"Starr","year":"2016"},{"key":"10.1016\/j.lfs.2025.124176_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.663418","article-title":"Pituitary adenylate cyclase-activating polypeptide in learning and memory","volume":"15","author":"Gilmartin","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.lfs.2025.124176_bb0300","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1007\/s12035-021-02381-2","article-title":"Pituitary adenylate cyclase-activating polypeptide protects against cognitive impairment caused by chronic cerebral hypoperfusion","volume":"58","author":"Guo","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2025.124176_bb0305","series-title":"Handbook of Hormones: Comparative Endocrinology for Basic and Clinical Research","first-page":"259","article-title":"Pituitary adenylate cyclase-activating polypeptide","author":"Nakamachi","year":"2021"},{"key":"10.1016\/j.lfs.2025.124176_bb0310","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1471-4159.2011.07330.x","article-title":"Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1","volume":"118","author":"Baxter","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2025.124176_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00377","article-title":"Protective effects of PACAP in peripheral organs","volume":"11","author":"Toth","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.lfs.2025.124176_bb0320","series-title":"PACAP Regulation of Inflammatory and Free Radical Networks in Neuronal and Nonneuronal Diseases","first-page":"671","author":"Ohtaki","year":"2016"},{"key":"10.1016\/j.lfs.2025.124176_bb0325","article-title":"Design and synthesis of brain penetrant glycopeptide analogues of PACAP with neuroprotective potential for traumatic brain injury and parkinsonism","volume":"1","author":"Apostol","year":"2021","journal-title":"Front. Drug Discov."},{"key":"10.1016\/j.lfs.2025.124176_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146858","article-title":"Effects of PACAP-38 and an analog, acetyl-[Ala15, Ala20] PACAP-38-propylamide, on memory consolidation in the detection of spatial novelty task in rats","volume":"1739","author":"Ladjimi","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2025.124176_bb0335","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/9781681082318116050006","article-title":"Recent perspective about the amyloid cascade hypothesis and stem cell-based therapy in the treatment of Alzheimer\u2019s disease","volume":"5","author":"Marei","year":"2016","journal-title":"Front. Clin. Drug Res. - Alzheimer Disord."},{"key":"10.1016\/j.lfs.2025.124176_bb0340","doi-asserted-by":"crossref","first-page":"12302","DOI":"10.1038\/s41598-023-39571-y","article-title":"PACAP activates MRGPRX2 on meningeal mast cells to drive migraine-like pain","volume":"13","author":"Sbei","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.124176_bb0345","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2019.10.010","article-title":"Discovery of human signaling systems: pairing peptides to G protein-coupled receptors","volume":"179","author":"Foster","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2025.124176_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.08.003","article-title":"The amidated PACAP1\u201323 fragment is a potent reduced-size neuroprotective agent","volume":"1863","author":"Lamine","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.lfs.2025.124176_bb0355","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2015.01.009","article-title":"A structure\u2013function study of PACAP using conformationally restricted analogs: identification of PAC1 receptor-selective PACAP agonists","volume":"66","author":"Ramos-\u00c1lvarez","year":"2015","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.124176_bb0360","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.2174\/092986709789712899","article-title":"Pituitary adenylate cyclase-activating polypeptide: focus on structure - activity relationships of a neuroprotective peptide","volume":"16","author":"Bourgault","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lfs.2025.124176_bb0365","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuropharm.2015.05.014","article-title":"Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson\u2019s disease model","volume":"108","author":"Lamine","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2025.124176_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413660","article-title":"Metformin treatment attenuates brain inflammation and rescues pacap\/vip neuropeptide alterations in mice fed a high-fat diet","volume":"22","author":"Mandwie","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.124176_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114945","article-title":"Metformin in Alzheimer\u2019s disease: an overview of potential mechanisms, preclinical and clinical findings","volume":"197","author":"Khezri","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2025.124176_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102420","article-title":"The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex","volume":"9","author":"Hettich","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.124176_bb0385","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3233\/JAD-220180","article-title":"Association between metformin and Alzheimer\u2019s disease: a systematic review and meta-analysis of clinical observational studies","volume":"88","author":"Luo","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2025.124176_bb0390","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer\u2019s disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2025.124176_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108662","article-title":"Linagliptin, a DPP-4 inhibitor, ameliorates A\u03b2 (1\u221242) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer\u2019s disease","volume":"195","author":"Siddiqui","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2025.124176_bb0400","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1007\/s11064-023-03924-w","article-title":"Neuroprotective role of DPP-4 inhibitor linagliptin against neurodegeneration, neuronal insulin resistance and neuroinflammation induced by intracerebroventricular streptozotocin in rat model of Alzheimer\u2019s disease","volume":"48","author":"Siddiqui","year":"2023","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.lfs.2025.124176_bb0405","doi-asserted-by":"crossref","first-page":"22418","DOI":"10.1074\/jbc.M212355200","article-title":"The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: In vivo metabolism of pituitary adenylate cyclase-activating polypeptide-(1-38)","volume":"278","author":"Zhu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2025.124176_bb0410","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fimmu.2015.00386","article-title":"DPP4 in diabetes","volume":"6","author":"R\u00f6hrborn","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2025.124176_bb0415","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13195-023-01334-2","article-title":"PACAP\u2013Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer\u2019s disease","volume":"15","author":"Wang","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2025.124176_bb0420","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/02652048.2025.2500542","article-title":"Repurposing linagliptin-loaded novasomes as a neuroprotectant for Alzheimer\u2019s disease: in-vitro characterisation, statistical optimisation and ex-vivo permeation study","volume":"42","author":"Farag","year":"2025","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.lfs.2025.124176_bb0425","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-023-01360-0","article-title":"Statins and cognitive decline in patients with Alzheimer\u2019s and mixed dementia: a longitudinal registry-based cohort study","volume":"15","author":"Petek","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2025.124176_bb0430","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","article-title":"Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects","volume":"88","author":"Swiger","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2025.124176_bb0435","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13760-025-02758-3","article-title":"Statins and the risk of dementia: a meta-analysis","volume":"125","author":"Li","year":"2025","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.lfs.2025.124176_bb0440","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/anie.201204964","article-title":"Alzheimer\u2019s disease, cholesterol, and statins: the junctions of important metabolic pathways","volume":"52","author":"Silva","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.lfs.2025.124176_bb0445","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/1871527315666160518123727","article-title":"Targeting new pharmacological approaches for Alzheimer\u2019s disease: potential for statins and phosphodiesterase inhibitors","volume":"15","author":"Sallustio","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.lfs.2025.124176_bb0450","doi-asserted-by":"crossref","DOI":"10.12771\/emj.2023.e17","article-title":"Protective effects of statins against Alzheimer disease","volume":"46","author":"Rezakhani","year":"2023","journal-title":"Ewha Med. J."},{"key":"10.1016\/j.lfs.2025.124176_bb0455","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejim.2015.08.012","article-title":"Do statins prevent Alzheimer\u2019s disease? A narrative review","volume":"26","author":"Daneschvar","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.lfs.2025.124176_bb0460","article-title":"Statins for the prevention of dementia","volume":"2016","author":"Mcguinness","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2025.124176_bb0465","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1096\/fj.10-180133","article-title":"Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer\u2019s disease-like pathology in amyloid precursor protein-transgenic mice","volume":"25","author":"Rat","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2025.124176_bb0470","series-title":"PACAP signaling in neuroprotection","first-page":"549","author":"Manecka","year":"2016"},{"key":"10.1016\/j.lfs.2025.124176_bb0475","doi-asserted-by":"crossref","first-page":"9749","DOI":"10.1074\/jbc.M109.043117","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP)\/PAC 1HOP1 receptor activation coordinates multiple neurotrophic signaling pathways: Akt activation through phosphatidylinositol 3-kinase \u03b3 and vesicle endocytosis for neuronal survival","volume":"285","author":"May","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2025.124176_bb0480","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.3390\/ijms22168682","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP) in physiological and pathological processes within the gastrointestinal tract: a review","volume":"22","author":"Karpiesiuk","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.124176_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170645","article-title":"Changes of pituitary adenylate cyclase activating polypeptide (PACAP) level in polytrauma patients in the early post-traumatic period","volume":"146","author":"Tam\u00e1s","year":"2021","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.124176_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2021.818003","article-title":"Design and synthesis of brain penetrant glycopeptide analogues of PACAP With neuroprotective potential for traumatic brain injury and parkinsonism","volume":"1","author":"Apostol","year":"2022","journal-title":"Front. Drug Discov."},{"key":"10.1016\/j.lfs.2025.124176_bb0495","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/jcbfm.2008.131","article-title":"Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models","volume":"29","author":"Dogrukol-Ak","year":"2009","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.lfs.2025.124176_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.932099","article-title":"gH625-liposomes deliver PACAP through a dynamic in vitro model of the blood\u2013brain barrier","volume":"13","author":"Barra","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2025.124176_bb0505","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2015.01.009","article-title":"A structure\u2013function study of PACAP using conformationally restricted analogs: identification of PAC1 receptor-selective PACAP agonists","volume":"66","author":"Ramos-\u00c1lvarez","year":"2015","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.lfs.2025.124176_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00221","article-title":"Protective effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide against cognitive decline in neurodegenerative diseases","volume":"14","author":"Sol\u00e9s-Tarr\u00e9s","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.lfs.2025.124176_bb0515","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.regpep.2006.06.016","article-title":"Neuroprotection by endogenous and exogenous PACAP following stroke","volume":"137","author":"Chen","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.lfs.2025.124176_bb0520","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.2147\/IJN.S520768","article-title":"Brain delivery strategies for biomacromolecular drugs: intranasal administration","volume":"20","author":"Wu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2025.124176_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1118927","article-title":"Role of endocrine PACAP in age-related diseases","volume":"14","author":"Toth","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.lfs.2025.124176_bb0530","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.npep.2013.10.005","article-title":"PACAP and PAC1 receptor in brain development and behavior","volume":"47","author":"Shen","year":"2013","journal-title":"Neuropeptides"},{"key":"10.1016\/j.lfs.2025.124176_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.585082","article-title":"Intranasal administration of PACAP is an efficient delivery route to reduce infarct volume and promote functional recovery after transient and permanent middle cerebral artery occlusion","volume":"11","author":"Cherait","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.lfs.2025.124176_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2025.112633","article-title":"PACAP inhibits high fat-induced NLRP3 inflammasome-mediated pyroptosis in vascular endothelial cells by regulating the SIRT1\/ROS pathway","volume":"608","author":"Dong","year":"2025","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525008124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525008124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:02:00Z","timestamp":1767880920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525008124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":108,"alternative-id":["S0024320525008124"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.124176","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PACAP: A promising disease-modifying target for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.124176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124176"}}